Giuseppe Curigliano to Chemotherapy, Adjuvant
This is a "connection" page, showing publications Giuseppe Curigliano has written about Chemotherapy, Adjuvant.
Connection Strength
0.972
-
Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer. Curr Opin Oncol. 2019 11; 31(6):472-479.
Score: 0.158
-
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer. Expert Rev Clin Pharmacol. 2019 Jan; 12(1):9-16.
Score: 0.149
-
Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. Eur J Cancer. 2018 07; 97:1-6.
Score: 0.143
-
Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. Eur J Cancer. 2017 12; 87:164-171.
Score: 0.138
-
Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. Curr Opin Oncol. 2017 Nov; 29(6):428-433.
Score: 0.138
-
Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer. J Clin Oncol. 2017 Aug 10; 35(23):2600-2603.
Score: 0.135
-
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. Eur J Cancer. 2019 10; 120:1-9.
Score: 0.039
-
Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. Eur J Cancer. 2019 09; 118:41-48.
Score: 0.039
-
Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. Breast. 2017 Aug; 34:89-95.
Score: 0.033